Janus kinases (JAKs) belong to the non-receptor tyrosine kinase family, and their JAK-STAT signaling pathway with signal transducers and activators of transcription (STAT) can affect cell proliferation, differentiation, apoptosis, and […]
B Cell Receptor (BCR) signaling pathway overview BCR is a transmembrane protein complex that controls B cell maturation, survival, apoptosis, and the production of plasma cell antibodies starting from the […]
Overview of cancer immunotherapy The most widely studied cancer immunotherapies are PD-1/PD-L1 immune checkpoint inhibitors and chimeric antigen receptor-T cell (CAR-T) therapy. With the expanded clinical applications, some defects of […]
Lung cancer is a major type of cancer in the world, with the highest morbidity and mortality among all malignant tumors. ALK-positive non-small cell lung cancer (ALK+ NSCLC) is a […]
Mutations in the epidermal growth factor receptor (EGFR) kinase domain are the oncogenic drivers of this adenocarcinoma. Tyrosine kinase inhibitors (TKIs), developed over the last two decades, targeting EGFR mutations, […]
1. Respiratory system 1.1. Lung cancer Drug Name Trade name CAS Target Description Approved Status Gefitinib lressa 184475-35-2 EGFR Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both […]
In 2007, Japanese professors firstly discovered ALK rearrangement and identified the fusion of ALK and EML4 in non-small cell lung cancer specimens. EML4 can promote the activation of ALK kinase […]
CDKs belong to the serine/threonine protein kinase family, and their kinase activity requires binding to cyclins. Abnormalities in CDKs have been reported to cause proliferation, genomic and chromosomal instability that […]
MYC protein is an inherently disordered protein, which lacks a hydrophobic pocket or groove suitable for binding small molecule compounds. Currently, no small molecule compounds that can bind MYC have […]